Chronic Myeloid Leukemia Coverage from Every Angle

Study Finds Novel Compound Reduces Survival of Imatinib-Resistant CML Cells

By: Sarah Campen, PharmD
Posted: Tuesday, March 12, 2019

A novel hybrid compound, NPQ-C6, appears to reduce the survival of chronic myeloid leukemia (CML) cells, even those resistant to imatinib. By inhibiting the STAT5 pathway, the naphthoquinone-coumarin conjugate blocks the expression of genes that facilitate cell-cycle progression, survival of CML cells, and oncogenesis. A study highlighting the compound as a “promising scaffold” for drug design was published in Frontiers in Pharmacology.

“These findings provide new insights into [the] molecular mechanism of naphthoquinone-coumarin conjugates in cancer,” stated Leandro Fernández-Pérez, MD, PhD, of the Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain, and colleagues. “[They] support its potential therapeutic application in BCR-ABL– and STAT5-related malignancies.”

The effects of NPQ-C6 were evaluated on human CML-derived K562 cells. The researchers found that NPQ-C6 triggered cell-cycle arrest by changing expression levels and/or phosphorylation of many proteins involved in cell-cycle progression. The compound also induced apoptosis in K562 cells, possibly by initiating the mitochondrial apoptotic pathway.

NPQ-C6 decreased levels of PIM-1, a protein that promotes cell cycling, proliferation, and cell survival in hematologic malignancies. Dr. Fernández-Pérez and colleagues noted that targeting PIM kinases “may provide a unique therapeutic approach for the treatment of BCR-ABL1–positive leukemia.” Finally, NPQ-C6 was able to maintain its activity on the BCR-ABL1/STAT5/c-MYC/PIM-1 oncogenic pathway in imatinib-resistant cells, suggesting that naphthoquinone-coumarin conjugates could circumvent resistance to tyrosine kinase inhibitors in BCR-ABL1–positive leukemia.

Disclosure: The study authors reported no conflicts of interest.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.